Hypercoagulability, platelet function, inflammation and coronary artery disease acuity: Results of the Thrombotic RIsk Progression (TRIP) Study

Udaya S. Tantry, Kevin P. Bliden, Thomas A. Suarez, Rolf Kreutz, Joseph Dichiara, Paul A. Gurbel

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

The objective of the study was to determine the relation of platelet reactivity, hypercoagulability and inflammation in various stages of coronary artery disease acuity (CAD). Thrombin-induced platelet-fibrin clot strength (MA), time to initial platelet-fibrin clot formation (R), C-reactive protein (CRP), prothrombotic factors, activated GPIIb/IIIa receptor expression and other biomarkers were studied in patients with asymptomatic stable CAD (AS), in patients undergoing PCI for stable (SA) and unstable angina (UA). MA and R were measured by thrombelastography, GPIIb/IIIa expression by flow cytometry and all other markers by fluorokine multianalyte profiling assays. An overall increase in all measurements from a clinically stable to an unstable disease state was observed. There was a distinct stepwise increment in MA [AS vs. SA (p 0.02), SA vs. UA (p 0.02) and AS vs. UA (p <0.001)]. MA exhibited the strongest correlation with other prothrombotic markers (p ≤ 0.02), with CRP (p <0.001) at all levels of CAD acuity. A distinct pathophysiological state of heightened platelet function, hypercoagulability and inflammation marks the presence of unstable cardiovascular disease requiring intervention. Further studies are required to investigate the primary mechanisms linking the above processes associated with a prothrombotic state resulting in clinical destabilization of the disease.

Original languageEnglish (US)
Pages (from-to)360-367
Number of pages8
JournalPlatelets
Volume21
Issue number5
DOIs
StatePublished - 2010
Externally publishedYes

Fingerprint

Thrombophilia
Coronary Artery Disease
Unstable Angina
Blood Platelets
Inflammation
Fibrin
C-Reactive Protein
Patient Acuity
Thrombelastography
Platelet Glycoprotein GPIIb-IIIa Complex
Stable Angina
Thrombin
Flow Cytometry
Cardiovascular Diseases
Biomarkers

Keywords

  • Biomarker
  • Coronary artery disease
  • Inflammation
  • Platelet-fibrin clot strength
  • Thrombosis

ASJC Scopus subject areas

  • Hematology
  • Medicine(all)

Cite this

Hypercoagulability, platelet function, inflammation and coronary artery disease acuity : Results of the Thrombotic RIsk Progression (TRIP) Study. / Tantry, Udaya S.; Bliden, Kevin P.; Suarez, Thomas A.; Kreutz, Rolf; Dichiara, Joseph; Gurbel, Paul A.

In: Platelets, Vol. 21, No. 5, 2010, p. 360-367.

Research output: Contribution to journalArticle

Tantry, Udaya S. ; Bliden, Kevin P. ; Suarez, Thomas A. ; Kreutz, Rolf ; Dichiara, Joseph ; Gurbel, Paul A. / Hypercoagulability, platelet function, inflammation and coronary artery disease acuity : Results of the Thrombotic RIsk Progression (TRIP) Study. In: Platelets. 2010 ; Vol. 21, No. 5. pp. 360-367.
@article{7a2bef12d0da4048aa58056e90f9e893,
title = "Hypercoagulability, platelet function, inflammation and coronary artery disease acuity: Results of the Thrombotic RIsk Progression (TRIP) Study",
abstract = "The objective of the study was to determine the relation of platelet reactivity, hypercoagulability and inflammation in various stages of coronary artery disease acuity (CAD). Thrombin-induced platelet-fibrin clot strength (MA), time to initial platelet-fibrin clot formation (R), C-reactive protein (CRP), prothrombotic factors, activated GPIIb/IIIa receptor expression and other biomarkers were studied in patients with asymptomatic stable CAD (AS), in patients undergoing PCI for stable (SA) and unstable angina (UA). MA and R were measured by thrombelastography, GPIIb/IIIa expression by flow cytometry and all other markers by fluorokine multianalyte profiling assays. An overall increase in all measurements from a clinically stable to an unstable disease state was observed. There was a distinct stepwise increment in MA [AS vs. SA (p 0.02), SA vs. UA (p 0.02) and AS vs. UA (p <0.001)]. MA exhibited the strongest correlation with other prothrombotic markers (p ≤ 0.02), with CRP (p <0.001) at all levels of CAD acuity. A distinct pathophysiological state of heightened platelet function, hypercoagulability and inflammation marks the presence of unstable cardiovascular disease requiring intervention. Further studies are required to investigate the primary mechanisms linking the above processes associated with a prothrombotic state resulting in clinical destabilization of the disease.",
keywords = "Biomarker, Coronary artery disease, Inflammation, Platelet-fibrin clot strength, Thrombosis",
author = "Tantry, {Udaya S.} and Bliden, {Kevin P.} and Suarez, {Thomas A.} and Rolf Kreutz and Joseph Dichiara and Gurbel, {Paul A.}",
year = "2010",
doi = "10.3109/09537100903548903",
language = "English (US)",
volume = "21",
pages = "360--367",
journal = "Platelets",
issn = "0953-7104",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Hypercoagulability, platelet function, inflammation and coronary artery disease acuity

T2 - Results of the Thrombotic RIsk Progression (TRIP) Study

AU - Tantry, Udaya S.

AU - Bliden, Kevin P.

AU - Suarez, Thomas A.

AU - Kreutz, Rolf

AU - Dichiara, Joseph

AU - Gurbel, Paul A.

PY - 2010

Y1 - 2010

N2 - The objective of the study was to determine the relation of platelet reactivity, hypercoagulability and inflammation in various stages of coronary artery disease acuity (CAD). Thrombin-induced platelet-fibrin clot strength (MA), time to initial platelet-fibrin clot formation (R), C-reactive protein (CRP), prothrombotic factors, activated GPIIb/IIIa receptor expression and other biomarkers were studied in patients with asymptomatic stable CAD (AS), in patients undergoing PCI for stable (SA) and unstable angina (UA). MA and R were measured by thrombelastography, GPIIb/IIIa expression by flow cytometry and all other markers by fluorokine multianalyte profiling assays. An overall increase in all measurements from a clinically stable to an unstable disease state was observed. There was a distinct stepwise increment in MA [AS vs. SA (p 0.02), SA vs. UA (p 0.02) and AS vs. UA (p <0.001)]. MA exhibited the strongest correlation with other prothrombotic markers (p ≤ 0.02), with CRP (p <0.001) at all levels of CAD acuity. A distinct pathophysiological state of heightened platelet function, hypercoagulability and inflammation marks the presence of unstable cardiovascular disease requiring intervention. Further studies are required to investigate the primary mechanisms linking the above processes associated with a prothrombotic state resulting in clinical destabilization of the disease.

AB - The objective of the study was to determine the relation of platelet reactivity, hypercoagulability and inflammation in various stages of coronary artery disease acuity (CAD). Thrombin-induced platelet-fibrin clot strength (MA), time to initial platelet-fibrin clot formation (R), C-reactive protein (CRP), prothrombotic factors, activated GPIIb/IIIa receptor expression and other biomarkers were studied in patients with asymptomatic stable CAD (AS), in patients undergoing PCI for stable (SA) and unstable angina (UA). MA and R were measured by thrombelastography, GPIIb/IIIa expression by flow cytometry and all other markers by fluorokine multianalyte profiling assays. An overall increase in all measurements from a clinically stable to an unstable disease state was observed. There was a distinct stepwise increment in MA [AS vs. SA (p 0.02), SA vs. UA (p 0.02) and AS vs. UA (p <0.001)]. MA exhibited the strongest correlation with other prothrombotic markers (p ≤ 0.02), with CRP (p <0.001) at all levels of CAD acuity. A distinct pathophysiological state of heightened platelet function, hypercoagulability and inflammation marks the presence of unstable cardiovascular disease requiring intervention. Further studies are required to investigate the primary mechanisms linking the above processes associated with a prothrombotic state resulting in clinical destabilization of the disease.

KW - Biomarker

KW - Coronary artery disease

KW - Inflammation

KW - Platelet-fibrin clot strength

KW - Thrombosis

UR - http://www.scopus.com/inward/record.url?scp=77954807956&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954807956&partnerID=8YFLogxK

U2 - 10.3109/09537100903548903

DO - 10.3109/09537100903548903

M3 - Article

C2 - 20377327

AN - SCOPUS:77954807956

VL - 21

SP - 360

EP - 367

JO - Platelets

JF - Platelets

SN - 0953-7104

IS - 5

ER -